Yuhan Corporation

KOSE:A000100 Voorraadrapport

Marktkapitalisatie: ₩10.6t

Yuhan Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Yuhan is de winst gegroeid met een gemiddeld jaarlijks percentage van 3.6%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 11.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 5.3% per jaar. Het rendement op eigen vermogen van Yuhan is 6.9%, en het heeft een nettomarge van 7.8%.

Belangrijke informatie

3.6%

Groei van de winst

2.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie11.3%
Inkomstengroei5.3%
Rendement op eigen vermogen6.9%
Nettomarge7.8%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26
Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Recent updates

Is Yuhan (KRX:000100) Using Too Much Debt?

Oct 08
Is Yuhan (KRX:000100) Using Too Much Debt?

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Sep 16
Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Aug 28
Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01
Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13
Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26
Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13
Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11
Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01
Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16
Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15
Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25
Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10
Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28
Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13
The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Dec 31
Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Dec 18
Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Dec 05
Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20
Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Opbrengsten en kosten

Hoe Yuhan geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

KOSE:A000100 Opbrengsten, kosten en inkomsten (KRW Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241,893,119147,849385,446146,919
31 Mar 241,860,529124,466378,998130,975
31 Dec 231,858,984133,993370,027119,920
30 Sep 231,872,33688,109365,050117,355
30 Jun 231,820,81176,045350,511114,124
31 Mar 231,808,041101,446355,579111,826
31 Dec 221,775,84795,144356,575107,103
30 Sep 221,749,31574,669359,069116,405
30 Jun 221,769,24597,836362,073112,866
31 Mar 221,719,63097,911355,095108,107
31 Dec 211,687,810102,583346,977106,677
30 Sep 211,725,26198,128350,567121,027
30 Jun 211,703,47597,833333,638128,767
31 Mar 211,685,62397,578321,279141,056
31 Dec 201,619,865192,761309,459142,634
30 Sep 201,552,188184,730292,514124,020
30 Jun 201,504,765168,667292,671109,357
31 Mar 201,448,677140,227291,60396,264
31 Dec 191,480,35440,006298,24996,900
30 Sep 191,500,78244,230295,95884,846
30 Jun 191,497,13041,438289,46086,652
31 Mar 191,523,95452,333285,11381,152
31 Dec 181,518,82357,481272,19974,067
30 Sep 181,481,90670,146260,11278,217
30 Jun 181,482,03484,572255,01172,563
31 Mar 181,450,870100,288254,54570,132
31 Dec 171,462,248109,034251,73371,435
30 Sep 171,434,749139,325247,12863,536
30 Jun 171,417,835137,434242,25360,608
31 Mar 171,395,518139,440233,21057,434
31 Dec 161,320,797161,249228,04852,667
30 Sep 161,274,011134,997229,65550,435
30 Jun 161,223,925155,819221,36848,078
31 Mar 161,163,130152,682209,37143,881
31 Dec 151,128,731126,047206,75639,016
30 Sep 151,097,229118,104199,13534,597
30 Jun 151,046,71698,362199,29730,754
31 Mar 151,031,87594,628202,27131,270
31 Dec 141,017,49290,948202,25930,915
30 Sep 141,007,10995,434200,30731,018
30 Jun 14970,25387,696192,80731,896
31 Mar 14953,19183,863193,99331,378
31 Dec 13943,60986,461192,51532,027

Kwaliteitswinsten: A000100 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (7.8%) A000100 } zijn hoger dan vorig jaar (4.2%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van A000100 is de afgelopen 5 jaar met 3.6% per jaar gegroeid.

Versnelling van de groei: De winstgroei van A000100 over het afgelopen jaar ( 94.4% ) overtreft het 5-jarig gemiddelde ( 3.6% per jaar).

Winst versus industrie: De winstgroei A000100 over het afgelopen jaar ( 94.4% ) overtrof de Pharmaceuticals -sector 21.9%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 6.9% ) van A000100 wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden